CN104398701B - The extracting method of traditional medicine volatile oil extract component group for treating psoriasis a kind of and its application - Google Patents
The extracting method of traditional medicine volatile oil extract component group for treating psoriasis a kind of and its application Download PDFInfo
- Publication number
- CN104398701B CN104398701B CN201410733406.0A CN201410733406A CN104398701B CN 104398701 B CN104398701 B CN 104398701B CN 201410733406 A CN201410733406 A CN 201410733406A CN 104398701 B CN104398701 B CN 104398701B
- Authority
- CN
- China
- Prior art keywords
- volatile oil
- blood
- traditional medicine
- component group
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000341 volatile oil Substances 0.000 title claims abstract description 50
- 201000004681 Psoriasis Diseases 0.000 title claims abstract description 21
- 239000003814 drug Substances 0.000 title claims abstract description 19
- 239000000284 extract Substances 0.000 title claims abstract description 14
- 238000000034 method Methods 0.000 title claims abstract description 11
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 claims abstract description 16
- 238000000605 extraction Methods 0.000 claims abstract description 11
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 claims abstract description 9
- AGUISGUERLMHFF-PKIAMQTDSA-N (1s,4r,5s,8r)-1,8-dimethyl-4-propan-2-ylspiro[4.5]decane-3,9-dione Chemical compound CC(C)[C@H]1C(=O)C[C@H](C)[C@]11CC(=O)[C@H](C)CC1 AGUISGUERLMHFF-PKIAMQTDSA-N 0.000 claims abstract description 8
- 240000005001 Paeonia suffruticosa Species 0.000 claims abstract description 8
- 235000003889 Paeonia suffruticosa Nutrition 0.000 claims abstract description 8
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 claims abstract description 8
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 claims abstract description 8
- LAEJTNRXQGCKMM-UHFFFAOYSA-N Acorone Natural products CC(C)C1CC(=O)C(C)C12CCC(C)C(=O)C2 LAEJTNRXQGCKMM-UHFFFAOYSA-N 0.000 claims abstract description 7
- 244000001632 Acorus gramineus Species 0.000 claims abstract description 7
- 235000013073 Acorus gramineus Nutrition 0.000 claims abstract description 7
- 240000004980 Rheum officinale Species 0.000 claims abstract description 7
- 235000008081 Rheum officinale Nutrition 0.000 claims abstract description 7
- AGUISGUERLMHFF-UHFFFAOYSA-N epiacorone Natural products CC(C)C1C(=O)CC(C)C11CC(=O)C(C)CC1 AGUISGUERLMHFF-UHFFFAOYSA-N 0.000 claims abstract description 7
- 238000001256 steam distillation Methods 0.000 claims abstract description 6
- RKFAZBXYICVSKP-AATRIKPKSA-N alpha-asarone Chemical compound COC1=CC(OC)=C(\C=C\C)C=C1OC RKFAZBXYICVSKP-AATRIKPKSA-N 0.000 claims description 16
- 239000000126 substance Substances 0.000 claims description 9
- RKFAZBXYICVSKP-UHFFFAOYSA-N beta- asarone Natural products COC1=CC(OC)=C(C=CC)C=C1OC RKFAZBXYICVSKP-UHFFFAOYSA-N 0.000 claims description 7
- RKFAZBXYICVSKP-WAYWQWQTSA-N beta-asarone Chemical compound COC1=CC(OC)=C(\C=C/C)C=C1OC RKFAZBXYICVSKP-WAYWQWQTSA-N 0.000 claims description 7
- 238000004458 analytical method Methods 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 238000007654 immersion Methods 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 239000008280 blood Substances 0.000 abstract description 38
- 210000004369 blood Anatomy 0.000 abstract description 38
- 230000003213 activating effect Effects 0.000 abstract description 5
- 238000001816 cooling Methods 0.000 abstract description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000013641 positive control Substances 0.000 description 4
- 230000036760 body temperature Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical group CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241001674048 Phthiraptera Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- PQPVPZTVJLXQAS-UHFFFAOYSA-N hydroxy-methyl-phenylsilicon Chemical compound C[Si](O)C1=CC=CC=C1 PQPVPZTVJLXQAS-UHFFFAOYSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001185 psoriatic effect Effects 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of extracting method for treating psoriasis traditional medicine volatile oil extract component group and application.Rheum officinale, the root bark of tree peony, the radix paeoniae rubrathe, grass-leaved sweetflag according to a certain weight ratio, are soaked after crushing, steam distillation extraction volatile oil.The traditional medicine volatile oil extract has 70 kinds of volatile oil components through GC MS analyses, wherein β asarones account for 30.8% 36.2%, Paeonol 14.8% 18.2%, α asarones 3.8% 7.4%, acorone 3.8% 5.2%, blood-head blood stasis model rat temperature and whole blood, Plasma Viscosity can substantially be reduced, acted on cooling and activating blood, available for preparing psoriasis purposes.
Description
First, technical field
The present invention relates to technical field of Chinese medicine, specifically a kind of traditional medicine volatile oil extract for treating psoriasis into
Divide extracting method and its application of group.
2nd, background technology
Psoriasis is equivalent to the category such as traditional Chinese medicine " white ", " psoriasis ", " chronic eczema ", " snake lice ", and modern times, doctor recognized mostly
For this disease appearing in blood system, pathogenesis can substantially be summarized as that blood-head, blood stasis, blood is dry and the deficiency of blood, and blood is dry, the deficiency of blood is pathological characteristic,
It is the pathological examination that blood-head, blood stasis further develop.Therefore, emphasize that only blood-head and blood stasis are through in the treatment of psoriasis
The pathological characteristic of psoriasis all the time.
Chinese traditional treatment psoriasis often based on cool blood dissipates the stasis of blood medicine, reaches cooling and activating blood effect, and tool has a better effect.Chinese medicine
Rheum officinale clearing heat-fire, root bark of tree peony cool blood dissipates the stasis of blood, radix paeoniae rubrathe cooling and activating blood, grass-leaved sweetflag inducing resuscitation of having one's ideas straightened out.Therefore, the present invention is steamed using water vapour
Evaporate method extraction and prepare the Chinese medicine composition extractive of volatile oil, its cooling and activating blood acts on the model evaluation of blood-head rat's blood stasis model, uses
In the purposes for the treatment of psoriasis.
3rd, the content of the invention
For the demand of clinical psoriatic, the object of the present invention is to provide one kind to treat psoriasis extractive of volatile oil
The extracting method of components group and its application.
The purpose of the present invention is realized by following technical solution：
1. a kind of extracting method for treating psoriasis traditional medicine volatile oil extract component group, extraction step are as follows：
(1) raw material:1-5 parts of rheum officinale, 1-5 parts of the root bark of tree peony, 1-5 parts of the radix paeoniae rubrathe, 1-6 parts of grass-leaved sweetflag；
(2) above-mentioned raw materials medicinal powder is broken to 20-60 mesh, adds 5-20 times to measure water immersion 5-12h, steam distillation extraction 4-
8 it is small when, collect extractive of volatile oil；
(3) Analysis of Essential Oil Components：Extractive of volatile oil has 70 kinds of volatile oil components, wherein β-asarum through GC-MS analyses
Ether accounts for 30.8%-36.2%, Paeonol 14.8%-18.2%, α-asarone 3.8%-7.4%, acorone 3.8%-5.2%.
2. a kind of traditional medicine volatile oil extract component group is preparing the application in treating psoriasis.
Beneficial effect：
The traditional medicine volatile oil extract component group of the present invention, mainly by beta-Asarone, Paeonol, α-asarone, acorone
Deng more than 70 a volatile oil component compositions, blood-head blood stasis model rat temperature and whole blood, Plasma Viscosity can be significantly reduced, there is cool blood work
Blood acts on, available for treatment psoriasis purposes.
4th, the pharmacological testing of volatile oil component group
1. modeling and administration
Male SD rat is randomly divided into 4 groups, and every group 8, be respectively blank control group (physiological saline group), and model group is (dry
Yeast group), positive controls (dry ferment+aspirin group), medicine group (dry ferment+extractive of volatile oil group).Each group is pressed
10mL·kg-1Gastric infusion 1 time daily, continuous 7d.(blank control group is in hypodermic injection equivalent for modeling after the 6th day administration 1h
Physiological saline, remaining each group is in hypodermic injection dry ferment suspension, injection dosage 10mLkg-1), record anus temperature in rat 6h
Change, fasting 10h, gastric infusion 1h rear neck arteries take blood 5ml in added with 0.038gml within the 7th day-1The centrifugation of sodium citrate
Guan Zhong, with 3000rmin-1Rotating speed centrifuges 10min, takes upper plasma to measure plasma viscosity, separately takes whole blood to measure whole blood in right amount
It is high, medium and low to cut viscosity.
Statistics carries out data double sample t inspections and variance analysis using SPSS13.0 statistical softwares, experimental data with
Represent.
2. the influence pair blood-head rat's blood stasis model body temperature
Experimental result (table 1) shows：Blood-head blood stasis model group rat is significantly raised in 5h, 6h body temperature, model group and sky
White group comparing difference has conspicuousness (P ＜ 0.01).Compared with model group, positive controls can reduce the body of fever rat in 6h
Warm P ＜ 0.05)；Extractive of volatile oil significantly reduces the body temperature (P ＜ 0.05) of fever rat between 5h.
Rectal temperature test result in 1 rat 6h of table (N=8)
Note：* P ﹤ 0.05, * * P ﹤ 0.01
3. the influence pair blood-head rat's blood stasis model whole blood viscosity
Experimental result (table 2) shows：The high, medium and low viscosity of cutting of the whole blood of model group significantly raises (P ＜ compared with blank group
0.01).Compared with model group, positive controls can significantly reduce whole blood height cut, in cut viscosity (P ＜ 0.01), low shear viscosity (P
＜ 0.05)；Extractive of volatile oil can significantly reduce that whole blood is high, medium and low to cut viscosity (P ＜ 0.01).
2 rat whole blood viscosity measurements of table (N=8)
Note：* P ﹤ 0.05, * * P ﹤ 0.01
3. the influence pair blood-head rat's blood stasis model Plasma Viscosity
Experimental result (table 3)：Compared with blank group, model group plasma viscosity has significant difference (P ＜ 0.01).With model
Group compares, and positive controls, extractive of volatile oil can reduce Plasma Viscosity (P ＜ 0.05).
3 rat plasma viscosity measurement result of table (N=8)
Note：* P ﹤ 0.05, * * P ﹤ 0.01
5th, volatile oil extracting chemical constituent GC-MS is analyzed
Chromatographic column HP-5MS Phenyl Methyl Siloxane quartz capillary chromatographic columns (0.25mm × 30m, 0.25 μ
m)；Carrier gas is helium, 1 μ L of sample size, 1 μ LmL of flow velocity-1, split ratio 20: 1,250 DEG C of injector temperature, detector temperature 250
℃；Temperature programming：70 DEG C of initial temperature, keeps 2min, is warming up to 150 DEG C with 2 DEG C/min speed, keeps 10min, with 2 DEG C/
The speed of min is warming up to 180 DEG C, keeps 20min, is warming up to 230 DEG C with the speed of 2 DEG C/min, keeps 5min.Mass resolution
500, ionize mode EI, electron energy 70eV, 200 DEG C, accelerating potential 4kV, sweep speed 1sdec of ion source temperature-1, scanning
Scope m/z20~500.
It is automatic to its memory spectrum storehouse through data handling system using GC-MS analysis volatile oil extracting chemical constituents (Fig. 1)
Retrieval, artificial spectrum elucidation, with reference to documents and materials, identifies 70 compounds (table 3), accounts for the 90.1%- of total volatile oil amount
95.4%, wherein beta-Asarone accounts for 32.1%-38.8%, Paeonol 10.2%-18.2%, α-asarone 3.5%-7.4%, Chang
Pu ketone 2.2%-6.2%.
3 extractive of volatile oil component of table
Show through result of study, the extractive of volatile oil components group prepared by the present invention, mainly by beta-Asarone, the root bark of tree peony
More than 70 a volatile oil component such as phenol, α-asarone, acorone forms, and can substantially reduce blood-head blood stasis model rat temperature and complete
Blood, Plasma Viscosity, have cooling and activating blood effect, available for preparing psoriasis purposes.
6th, illustrate
Fig. 1 extractive of volatile oil GC-MS total ion current figures.
Seven, embodiments
Embodiment 1：The extracting method of psoriasis traditional medicine volatile oil extract component group is treated, extraction step is as follows：
(1) bulk pharmaceutical chemicals:1 part of rheum officinale, 1 part of the root bark of tree peony, 1 part of the radix paeoniae rubrathe, 1 part of grass-leaved sweetflag；
(2) above-mentioned raw materials medicinal powder is broken to 20 mesh, adds 5 times of amount water immersion 5h, when steam distillation extraction 4 is small, collect
Extractive of volatile oil；
(3) Analysis of Essential Oil Components：With GC-MS analysis extractive of volatile oil chemical composition, share volatile oil more than 70 into
Point, wherein beta-Asarone accounts for 34.8%, Paeonol 14.8%, α-asarone 5.2%, acorone 3.8%.
Embodiment 2：The extracting method of psoriasis traditional medicine volatile oil extract component group is treated, extraction step is as follows：
(1) bulk pharmaceutical chemicals:3 parts of rheum officinale, 2 parts of the root bark of tree peony, 3 parts of the radix paeoniae rubrathe, 4 parts of grass-leaved sweetflag；
(2) above-mentioned raw materials medicinal powder is broken to 40 mesh, adds 10 times of amount water immersion 10h, when steam distillation extraction 6 is small, receive
Collect extractive of volatile oil；
(3) Analysis of Essential Oil Components：With GC-MS analysis extractive of volatile oil chemical composition, share volatile oil more than 70 into
Point, wherein beta-Asarone accounts for 30.8%, Paeonol 17.8%, α-asarone 3.8%, acorone 4.8%.
Embodiment 3：The extracting method of psoriasis traditional medicine volatile oil extract component group is treated, extraction step is as follows：
(1) bulk pharmaceutical chemicals:5 parts of rheum officinale, 5 parts of the root bark of tree peony, 5 parts of the radix paeoniae rubrathe, 6 parts of grass-leaved sweetflag；
(2) above-mentioned raw materials medicinal powder is broken to 60 mesh, adds 20 times of amount water immersion 12h, when steam distillation extraction 8 is small, receive
Collect extractive of volatile oil；
(3) Analysis of Essential Oil Components：With GC-MS analysis extractive of volatile oil chemical composition, share volatile oil more than 70 into
Point, wherein beta-Asarone accounts for 36.2%, Paeonol 18.2%, α-asarone 7.4%, acorone 5.2%.
Claims (2)
1. a kind of extracting method for the traditional medicine volatile oil extract component group for treating psoriasis, extraction step are as follows：
（1）Bulk pharmaceutical chemicals:1-5 parts of rheum officinale, 1-5 parts of the root bark of tree peony, 1-5 parts of the radix paeoniae rubrathe, 1-6 parts of grass-leaved sweetflag；
（2）Above-mentioned raw materials medicinal powder is broken to 20-60 mesh, adds 5-20 times to measure water immersion 5-12h, it is small that steam distillation extracts 4-8
When, collect extractive of volatile oil；
（3）Analysis of Essential Oil Components：Extractive of volatile oil GC-MS analyses have 70 kinds of volatile oil components, and wherein beta-Asarone accounts for
30.8%-36.2%, Paeonol 14.8%-18.2%, α-asarone 3.8%-7.4%, acorone 3.8%-5.2%.
2. traditional medicine volatile oil extract component group as claimed in claim 1 is preparing the application in treating psoriasis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410733406.0A CN104398701B (en) | 2014-12-04 | 2014-12-04 | The extracting method of traditional medicine volatile oil extract component group for treating psoriasis a kind of and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410733406.0A CN104398701B (en) | 2014-12-04 | 2014-12-04 | The extracting method of traditional medicine volatile oil extract component group for treating psoriasis a kind of and its application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104398701A CN104398701A (en) | 2015-03-11 |
| CN104398701B true CN104398701B (en) | 2018-04-17 |
Family
ID=52636410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410733406.0A Expired - Fee Related CN104398701B (en) | 2014-12-04 | 2014-12-04 | The extracting method of traditional medicine volatile oil extract component group for treating psoriasis a kind of and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104398701B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101199663A (en) * | 2006-12-14 | 2008-06-18 | 黑龙江福和华星制药集团股份有限公司 | Chinese medicine for treating psoriasis and preparing method thereof |
-
2014
- 2014-12-04 CN CN201410733406.0A patent/CN104398701B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101199663A (en) * | 2006-12-14 | 2008-06-18 | 黑龙江福和华星制药集团股份有限公司 | Chinese medicine for treating psoriasis and preparing method thereof |
Non-Patent Citations (4)
| Title |
|---|
| 从瘀热互结探讨银屑病的证治;李东海等;《辽宁中医药大学学报》;20100331;第12卷(第3期);第74页最后1段 * |
| 实验性淤热证大鼠模型的初步研究;许立等;《时珍国医国药》;20081231;第19卷(第12期);第2896-2897页 * |
| 研究周仲瑛"瘀热"学说的思路与方法;吴勉华等;《中华中医药杂志》;20091031;第24卷(第10期);第1321页左栏第3段第12-15行 * |
| 论瘀热;周仲瑛;《南京中医药大学学报》;20060930;第22卷(第5期);第273-331页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104398701A (en) | 2015-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chackrewarthy et al. | Evaluation of the hypoglycemic and hypolipidemic effects of an ethylacetate fraction of Artocarpus heterophyllus (jak) leaves in streptozotocin-induced diabetic rats | |
| CN103952240B (en) | A kind of preparation method of Flower of Sunset Abelmoschus volatile oil | |
| CN104825463B (en) | The Metabolism regulation of plain boiled pork Ganodenna Lucidum P.E and the purposes of anti anoxia | |
| Gonçalves et al. | Byproduct generated during the elaboration process of isotonic beverage as a natural source of bioactive compounds | |
| Noori et al. | Subcritical Water Extraction of Essential Oils from Matricaria Chamomilla L. | |
| CN102302553A (en) | Extraction method of key components of Chinese magnoliavine fruit medicament | |
| CN103540405A (en) | Method for preparing aromatic plant essential oil by using subcritical CO2 fluid extraction technology | |
| CN104398701B (en) | The extracting method of traditional medicine volatile oil extract component group for treating psoriasis a kind of and its application | |
| CN101961376A (en) | Method for refining sweet basil herb extract | |
| CN105031070A (en) | Viola tricolor extract for treating gouty arthritis and preparation method thereof | |
| Liu et al. | Review on the toxic effects of radix Bupleuri | |
| CN104178350A (en) | Method for separating and extracting chrysanthemum volatile oil, fiavonoid and phenolic acids from chrysanthemum | |
| CN104587103B (en) | A kind of extracting method that treating hemorrhagic stroke traditional medicine volatile oil extract component group and its application | |
| CN103535726B (en) | A kind of compound combination with collaborative effect of scavenging radical | |
| CN103239491B (en) | Sweetsop fatty acid with antineoplastic activity and fatty acid methyl ester effective part thereof | |
| CN106946680A (en) | A kind of medicine for adjusting diabetes blood fat | |
| CN109045088A (en) | A method of Radix Angelicae Sinensis effective component is extracted using diacolation technology | |
| CN105663097B (en) | A kind of sesquiterpenoid is preparing the application in inhibiting acute inflammation drug | |
| Aboutabl et al. | Bioactive lignans and other phenolics from the roots, leaves and seeds of Arctium lappa L. grown in Egypt | |
| Zhang et al. | Analysis of Chemical Constituents of Volatile Oil of Se-Enriched Selenium Codonopsis tangshen Oliv. GC-MS | |
| CN104435318B (en) | A kind of extracting method for treating hemorrhagic stroke Chinese medical extract components group and application | |
| CN105816814B (en) | Compound traditional Chinese medicine composition for treating non-alcoholic fatty liver disease and preparation method and application thereof | |
| CN104530749A (en) | Method for extracting natural pigment from bark | |
| CN105853472A (en) | Arkshell essential oil and preparation method thereof | |
| CN108379314A (en) | A kind of Chinese medical extract extracting method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180417 Termination date: 20181204 |